[Percutaneous treatment of intermediate- and high-risk pulmonary embolism: two case reports]

G Ital Cardiol (Rome). 2022 Jul;23(7 Suppl 2):22S-24S. doi: 10.1714/3838.38224.
[Article in Italian]

Abstract

Pulmonary embolism is the third most common cause of cardiovascular emergency. Risk stratification is crucial in the clinical and therapeutic management of these patients. The latest European guidelines introduced a new classification based on short-term mortality risk stratification, dividing patients into four categories (high, intermediate-high, intermediate-low and low risk). Despite the limited evidence in this field, the percutaneous treatment of pulmonary embolism represents an option of interest; however, correct patient selection and device choice should be better investigated. In this article, we present two case reports of patients with intermediate-high-risk and high-risk pulmonary embolism treated with the EkoSonic Endovascular System (EKOS Corp., Bothell, WA, USA) and the FlowTriever System (Inari Medical, Irvine, CA, USA), respectively.

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Pulmonary Embolism* / drug therapy
  • Thrombolytic Therapy*
  • Treatment Outcome